Deloitte expands Quartz AI suite with Atlas AI for drug discovery

Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates

USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr

Arco Lab now holds a 50% stake in Neviton

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)